Kornimate/medical-research-clean huggingface dataset:
analysis of remote-ischemic preconditioning effects on kidney function

Conditions: Renal Function; Renal Injury

Summary: patients with impaired renal function are at elevated risk for development of acute kidney injury (aki). aki is associated with increased risk for cardiovascular morbidity and mortality. effective aki prevention strategies are needed. remote ischemic preconditioning (ripc) is a novel and successful strategy to attenuate contrast medium induced aki in patients undergoing elective coronary angiography. the retrospective renpro-tavi trial was designed to test the hypothesis whether remote ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter aortic valve implantation (tavi). patients with impaired renal function undergoing tavi will be evaluated in respect whether they received remote ischemic preconditioning before the procedure or not. this study will give insight if ripc might be beneficial in these patients.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * impaired renal function (baseline egfr of \<60 ml/min) * high integer risk score \> 11 * high euroscore (european system for cardiac operative risk evaluation) exclusion criteria: * severe renal impairment (egfr \<15 ml/min and/or in chronic dialysis) * recent (\<=30 days) contrast media exposure * patients enrolled in concomitant studies * fertile women

Keywords: remote ischemic preconditioning acute kidney injury tavi renpro trial parameters
alk33-101: a study of rdc-0313 (alks 33) in adults with binge eating disorder

Conditions: Binge Eating Disorder

Summary: the purpose of this study is to evaluate the safety of daily doses of rdc-0313 (alks 33) compared with placebo in adults with binge-eating disorder (bed). an additional objective is to explore the efficacy of rdc-0313 treatment in comparison with placebo in adults with binge-eating disorder.

following screening, eligible subjects will be randomized in a 1:1 ratio to rdc-0313 (alks 33) or matching placebo. once-daily at-home dosing will begin at randomization and will continue for 6 weeks. there will be 8 study visits over a 12-week study period. on an ongoing basis, subjects will complete a take-home binge diary designed to record the number of binge-eating episodes (binge episodes) and binge-eating days (binge days, days during which at least 1 binge occurred), as well as snacks and meals consumed daily over each 7-day period.

Eligibility criteria:
inclusion criteria: * meet the diagnostic and statistical manual of mental disorders, 4th edition, text revised (dsm-iv-tr) criteria for a diagnosis of binge eating disorder (bed) * display greater than or equal to 3 binge eating days per week * body mass index (bmi) greater than or equal to 30 kg/m2 * age of 18 years or older * women of childbearing potential must agree to use an approved method of birth control for the duration of the study exclusion criteria: * concurrent symptoms of bulimia nervosa or anorexia nervosa * suicidal ideation * dsm-iv-tr diagnosis of substance abuse or dependence (except nicotine or caffeine) within 6 months prior to randomization * positive urine toxicological screen for benzodiazepines, opioids, amphetamine/methamphetamine, or cocaine at screening or randomization * women who are pregnant or breastfeeding * participation in a psychological or weight loss intervention for bed that was initiated within the 3 months prior to screening * clinically unstable medical disease * history of hepatitis b, hepatitis c, or human immunodeficiency virus (hiv) * history of seizures, including clinically significant febrile seizures in childhood * current or anticipated need for prescribed opioid medication during the study period * use of any psychotropic medications (other than hypnotics) * participation in a clinical trial of a pharmacological agent within 30 days prior to screening

Keywords: binge eating disorder rdc-0313
a long term follow-up study in participants treated in a preceding phase 2 or 3 study with a regimen containing odalasvir and al-335 with or without simeprevir for the treatment of hepatitis c virus (hcv) infection

Conditions: Hepatitis C

Summary: the main purpose of this study is to evaluate the durability of sustained virologic response (svr) in participants who achieved svr at last post-therapy visit of parent studies (lpvps) with nct numbers nct02569710 and nct02765490.

this multicentre study will not provide any study treatment but collect follow-up data for up to 3 years to assess the long term durability of svr achieved in one of the parent studies \[phase 2 or 3 with al-335 and odalasvir (odv) with or without simeprevir (smv\]. in addition participants who failed to achieve an svr in the parent study can be enrolled to assess the presence of resistance associated substitutions (ras) and their persistance over time. it is expected that the vast majority of approximately 250 participants will enrolled in the study. safety parameters and liver disease status will be assessed in all participants over time.

Eligibility criteria:
inclusion criteria: * participant was randomized to a regimen containing odalasvir (odv) with al-335 with or without simeprevir in a preceding phase 2 or phase 3 study (parent study) * participant received at least 1 dose of odv with al-335 with or without smv in the parent study * participant has completed the last post-therapy follow-up visit of the parent study ( lpvps) and has not passed the screening period of 6 + 3 months after the lpvps * participant has signed an informed consent form (icf) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study exclusion criteria: * participant is currently enrolled or plans to enroll in another study with an investigational drug (including investigational vaccines) or an invasive investigational medical device between the lpvps and visit 6 of the present study (36 months (+/-) 4 weeks after the lpvps of the parent study) * participant received antiviral or immunomodulating treatment, including therapeutic vaccines, for hcv infection between the lpvps and the screening visit of the present study, or is planned to receive such treatment during the period of this follow-up study * participant is not able to adhere to the requirements of the follow-up study
resistance training to improve fatigue and physical function in postmenopausal breast cancer survivors

Conditions: Cancer

Summary: this study will begin to fill a knowledge gap by determine whether changes in kynurenine metabolism occur following resistance training (rt) and relate to reductions in inflammation and improved behavioral and physical function as this may identify potential targets for interventions to promote cancer recovery.

interventions that reduce pro-inflammatory cytokines with resultant stimulation of kynurenine metabolism may be increasingly important in breast cancer survivors (bcs) to prevent susceptibility to cancer associated fatigue, depression, and declines in muscle mass and function. there is emerging evidence that supports exercise as a non-pharmacological therapy to prevent cancer recurrence, sedentary behaviors, and obesity during cancer survivorship . it seems that interventions that include resistance training (rt) are most efficacious at reducing fatigue in bcs this study will begin to fill a knowledge gap by determine whether changes in kynurenine metabolism occur following rt and relate to reductions in inflammation and improved behavioral and physical function as this may identify potential targets for interventions to promote cancer recovery.

Eligibility criteria:
inclusion criteria: 1. within 6 months to 10 years post active breast cancer therapy (i.e. surgery/chemotherapy) for stage i-iii invasive breast cancer, 2. at least 6 months post breast reconstruction (if applicable), 3. lack of menses for at least one year, 4. bmi 20-35 kg/m2, 5. fatigued (subjective reporting ≥3 on a 1-10 scale), 6. untrained with regard to structured resistance training (no more than 3x/week). exclusion criteria: 1. plans for surgery (e.g., breast reconstruction) during the study period, 2. taking an anticoagulant medication (i.e. heparin, apixaban, rivaroxaban), 3. allergic to lidocaine, 4. orthopedic or chronic pain condition restricting exercise, 5. mini-mental status examination (mmse) scores below education-specific cut-points (less than 23 for more than 9th grade education and less than 17 for less than 8th grade education), 6. unable to receive physician medical clearance.

Keywords: breast cancer survivors resistance training fatigue physical function behavioral function kynurenine metabolism
fluid balance, hormones and urine proteomics in nephrotic syndrome in childhood

Conditions: Nephrotic Syndrome

Summary: the purpose of this study is to describe the hormones controlling fluid balance in pediatric patients with nephrotic syndrome. further more, an analysis of the urinary and plasma proteins will be done using proteomics. different composition of proteins in the urine or plasma might indicate if the patients will respond to treatment or not.

nephrotic syndrome represents the association of proteinuria, hypoalbuminemia, oedema and hyperlipidemia. the pathogenesis of the oedemas remains controversial. the "underfill" theory is the traditional explanation where massive proteinuria leads to low plasma albumine and a subsequent decrease in intravascular osmotic pressure leading to edema formations. because most patients are normotensive and have normal intravascular pressure the "overfill" theory has been proposed suggesting a primary defect in renal sodium handling being responsible for oedema formation. ten percent of the children with nephrotic syndrome do not respond to standard steroid treatment and a significant proportion of these patients progress towards end-stage renal failure. at initial presentation it cannot be said if a patient will respond to treatment or not. the purposes of the sudy: 1. to describe changes in the hormones, aldosterone, atrial natriuretic peptide (anp), arginin vasopressin (avp), renin and angiotensin ii in patients with idiopathic nephrotic syndrome and to analyse to what extend the change in these hormones reflected a "underfill" or "overfill" situation. 2. to describe changes in the urine concentration of the water channel aqp ii and the sodium channel enac during the course of nephrotic syndrome. 3. to test the hypothesis that urine and plasma proteomics from patients with steroid resistant nephrotic syndrome differs from patients with steroid sensitive nephrotic syndrome. 50 pediatric patients with nephrotic syndrome will be included after informed consent from both parents. at day 1, 2, 3, 30 and 120 blood samples for hormones will be taken together with creatinin, albumine, na+, k+, hgb. an echocardiography will be performed at day 1 and day 30 to determine v. cava inferior index. at day 1,30 and 120 urine and plasma will be collected for proteomics and measurement of aqp ii and enac concentrations. further more a clinical examination will be performed at day 1, 2, 3, 30 and 120 and weight, blood pressure and response to treatment will be recorded.

Eligibility criteria:
inclusion criteria: * idiopathic nephrotic syndrome, age below 15 years exclusion criteria: * systemic disease e.g. henoch-schonleins purpura, lupus erythematosus, diabetes mellitus * age over 15 years * treatment with diuretics prior to baseline blood samples

Keywords: nephrotic syndrome underfill and overfill theory steroid resistance urine proteomics avp anp angiotensin ii renin and aldosterone
resting state functional magnetic resonance imaging study of jaundice infants before and after light treatment.

Conditions: Jaundice

Summary: it is just an observation study. the investigates want to explore the signal changes of resting state functional magnetic resonance imaging (fmri) after light treatment in jaundice infants. signal changes contain blood oxygenation level dependent (bold) and arterial spin labeling (asl).indicator of bold is amplitude of low-frequency fluctuation（alff).indicator of asl is cerebral blood flow (cbf). the investigates assume that the children with jaundice after light therapy, alff and cbf will change. focus on the globus pallidus and subthalamic nuclei. the two brain regions were proved to be abnormal in mri t1, t2 structure signal in kernicterus. doctors observe the status of infants aside.using monitoring probe can see clearly.

resting state fmri scan light therapy the second time resting state fmri scan

Eligibility criteria:
inclusion criteria: * hyperbilirubinemia exclusion criteria: * asphyxia * cerebral dysgenesis
a clinical study to evaluate the efficacy and safety of tqb3702 tablets combined with immunochemotherapy for the treatment of b-cell lymphoma

Conditions: B-cell Lymphoma

Summary: to evaluate the efficacy and safety of tqb3702 tablets combined with immunochemotherapy for the treatment of b-cell lymphoma


Eligibility criteria:
inclusion criteria: * the subjects voluntarily joined the study, signed the informed consent, and the compliance was good; * age: 18 years old ≤ age (when signing the informed consent) ≤75 years old; eastern cooperative oncology group (ecog) score: 0-2; expected survival of more than 3 months; * histologically confirmed b-cell lymphomas of the following types that meet the 2022 world health organization (who) diagnostic criteria: 1. relapsed/refractory indolent b-cell lymphoma 2. diffuse large b cell lymphoma（dlbcl） * previous treatment: relapsed/refractory inert b-cell lymphoma: have received at least one previous line of systemic standard therapy * have at least one measurable lesion. * the main organs function well. * female subjects of reproductive age should agree to use contraception (such as iuds, contraceptives, or condoms) during the study period and for 6 months after the end of the study; have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; male subjects should agree to use avoidance during the study period and for 6 months after the end of the study period. exclusion criteria: * have had or are currently suffering from other malignant tumors within 3 years prior to the first medication. * known or suspected central nervous system (cns) aggression. * relapsed/refractory inert b-cell lymphoma: previous allogeneic hematopoietic stem cell transplantation, or autologous hematopoietic stem cell transplantation within 3 months before the first treatment; * recurrent/refractory indolent b-cell lymphoma: toxic reactions that do not return to ≤ national cancer institute standard for common toxic reactions (nci-ctc) ae grade 1 due to any previous treatment, excluding hair loss and fatigue; * have multiple factors that affect oral drug absorption (such as inability to swallow, chronic diarrhea, and intestinal obstruction); * received major surgical treatment or significant traumatic injury within 28 days before the start of study treatment; * hyperkinetic/venous thrombosis events occurred within 6 months before the first medication; * have a history of psychotropic drug abuse and can not quit or have mental disorders; * subjects with any severe and/or uncontrolled disease; * received live vaccine or messenger ribonucleic acid (mrna) vaccine within 4 weeks before the first dose, or planned to receive live vaccine or mrna vaccine during the study; * participated in clinical trials of other antitumor drugs within 4 weeks before the first medication; * subjects who, in the judgment of the investigator, have concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are not suitable for enrollment for other reasons.
comparison of two types of splints to treat dental luxation injuries

Conditions: Dental Trauma; Splints

Summary: the objectives of this randomized clinical trial (rct) were: 1. to compare the efficiency of splinting by two composite materials in terms of retention of material 2. to compare adhesive point dimension between the two groups 3. to compare time taken to place and remove the splint 4. to assess the efficacy of bulkfill flowable in reducing mobility of luxated teeth.

a randomized control trial of 6 month period was done. patients with luxation injuries aged between 16- 50 years were asked to participate in the study after taking informed consent. they were then assigned to either group (group 1: packable composite (pc), group 2: bulkfill flowable) by lottery method. periotest was used to check the mobility of teeth before the placement of splint. splinting was performed with composite material according to group allocation. time taken to place the splint was recorded. frontal view images of splinted teeth were taken with dslr and transferred to adobe photoshop version 22.4.1 for windows to measure surface area of the restorative material in percentage to total tooth surface area. post-operative instructions were given. after 2 weeks, periotest readings were recorded, immediately after removal of splint. on both visits 3 readings per tooth were recorded. time taken to remove the splint was also recorded. additionally, the retention of splint was also observed. statistical analysis: spss version 26 for windows was used, the mean time taken to apply and remove the material and mobility before and after removal of splint was compared using the independent samples t test. mann-whitney test compared the percentage area of the material occupied. fisher's eaxct test evaluated the retention of splint material. level of significance was kept at p ≤0.05.

Eligibility criteria:
inclusion criteria: * permanent dentition patients aged between 16-50 years * either gender * lateral and extrusive luxation injuries exclusion criteria: * patients with following conditions were excluded * intrusion injuries * root fracture * dentoalveolar fracture. * patients with systemic diseases. * patients with periodontitis * para-functional habits * non-consenting patients

Keywords: dental trauma splints bulkfill composite packable composite
outcomes of an anticoagulation clinic in an university hospital

Conditions: Cardiopathy; Chagas Disease; Hemorrhage; Thrombosis

Summary: a clinical trial designed to compare the oral anticoagulation control obtained by an anticoagulation clinic and the usual medical care in chagas and non-chagas disease patients.

a randomized, crossover, clinical trial performed to compare the results of oral anticoagulation for chagas and non-chagas disease patients treated at an anticoagulation clinic and by the usual clinical practice. the primary endpoint was the time that the international normalized ratio (inr) was in the therapeutic range and the secondary endpoints were thromboembolic/haemorragic events.

Eligibility criteria:
inclusion criteria: * outpatients * chagas and non-chagas disease patients * any indication for chronic treatment with warfarin * anticoagulation for at least 30 days. exclusion criteria: * refusal to participate in the study; * use of phenprocoumon; * expectation of treatment lower than 1 year; * difficulties to attend medical visits; * participation in other prospective clinical study involving anticoagulation care during the study period.

Keywords: oral anticoagulants warfarin anticoagulation clinic thrombosis hemorrhage
quality of life and sexuality in patients with prostate cancer

Conditions: Quality of Life

Summary: the trial is to describe quality of life in patients affected by prostate cancer treated with exclusive radiotherapy and submitted to psychological and andrologic evaluation.

this trial is to describe quality of life and sexuality in patients with prostate cancer treated with exclusive radiotherapy. descriptive analysis of baseline characteristics will be performed by using appropriate summary measures for continous and categorical data. analysis of variation over time of fact scores will be conducted by means of anova analysis for repeated measures.

Eligibility criteria:
inclusion criteria: * age 18-75 years. * histologically-proven of prostate cancer * indication to radical radiotherapy on prostate/ prostate + seminal vesicles / prostate + seminal vesicles + pelvic lymph nodes * informed consent exclusion criteria: * other coexisting malignancies, uncontrolled intercurrent illness, active infectious processes, and exudative, bloody, or cytologically malignant effusions excluded patients from the trial. * previous surgery for prostate cancer, severe cardiac or vascular pathology * other major surgery in the preceding year or currently undergoing psychiatric care or psychological counseling.
acceleration of lower anterior teeth leveling and alignment using corticision

Conditions: Crowding, Tooth

Summary: this experimental study will evaluate the effect of corticision on accelerating the leveling and alignment of lower crowded incisors compared with the control untreated group using cone beam computed tomography. the study sample will consist of 26 patients with less than 6 mm crowding. the sample will be allocated randomly into two experimental groups. the brackets and passive ss wire will be applied with radiographic metal guides between each tooth to allow for accurate corticision site 2 mm below the gingival papilla and to prevent tooth roots injury. the dentoalveolar changes occurring after leveling and alignment of lower anterior teeth will be evaluated using cbct radiographs, frequency, degree of root resorption, and the incidence of bone dehiscence will be assessed in relation to initial situation.

crowding is the most common form of malocclusion. different methods have been used to resolve crowding, including extraction and nonextraction. corticision is an important methods to accelerate tooth movement in crowded cases. cortical bone incision without flap elevation enhances turnover rate of surrounding structures and decreases the time for leveling and alignment. in orthodontics, cbct imaging has been applied to evaluate impacted teeth and root resorption. but the data are very rare regarding the application of cbct in tooth movement. so cbct will be used in this research to evaluate the amount of external apical root resorption (earr) and presence of dehiscence in the lower anterior teeth in the crowded cases. furthermore, the duration of alignment will be compared between corticision group and non-corticision group.

Eligibility criteria:
inclusion criteria: * patients age 18 years or more * complete permanent dentition with second molars * crowding of less than 6 mm * good healthy patients without systematic diseases * absence of spaces in the lower dental arch * orthodontic treatment protocol does not required extraoral appliances, intraoral elastics, and expansion during leveling and alignment in the lower arch * good oral hygiene * absence of periodontal lesion exclusion criteria: * patients with syndromes, clefts, or craniofacial abnormalities or systematic diseases * poor oral hygiene or periodontal lesion * previous orthodontic treatment. * inability for brackets bonding in lower anterior teeth * presence of extreme skeletal discrepancy in vertical , transverse and anteroposterior relations * delay rebonding of any loosing brackets for more than one week in the lower anterior teeth

Keywords: corticision cbct crowding